Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131361) titled 'Mirvetuximab Soravtansine followed by other ADCs for platinum-resistant recurrent ovarian cancer' on Sept. 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Platinum-resistant recurrent ovarian cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-10
Target Sample Size: MIRV group:44;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=336417
Disclaimer: Curated by HT Syndication....